{"id":"NCT00996372","sponsor":"Sprout Pharmaceuticals, Inc","briefTitle":"Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women","officialTitle":"24-wk Efficacy and Safety of Flibanserin vs Pbo in Naturally Postmenopausal Women in United States","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2009-10-16","resultsPosted":"2014-06-12","lastUpdate":"2014-06-12"},"enrollment":949,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Sexual Dysfunctions, Psychological"],"interventions":[{"type":"DRUG","name":"flibanserin","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"flibanserin 100mg","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.","primaryOutcome":{"measure":"Change From Baseline in the Number of Satisfying Sexual Events","timeFrame":"baseline through 24 weeks","effectByArm":[{"arm":"Flibanserin 100mg","deltaMin":1,"sd":2.9},{"arm":"Placebo","deltaMin":0.6,"sd":2.8}],"pValues":[]},"eligibility":{"minAge":"35 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":8},"locations":{"siteCount":75,"countries":["United States"]},"refs":{"pmids":["24281236"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":468},"commonTop":["dizziness","nausea","headache","somnolence"]}}